Physician profile
Mohammad Athari
NPI 1831101583
$11,778.63
in general payments reported to CMS, 2019-2025
58 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,828 · 2020: $2,674 · 2021: $2,490 · 2022: $1,952 · 2023: $1,154 · 2024: $551 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $758.22 | 2021-2025 | Qulipta, Ubrelvy |
| Eisai INC. | $706.92 | 2019-2023 | |
| Sk Life Science, INC. | $685.86 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $641.90 | 2019-2023 | Austedo Xr, Ajovy, Austedo |
| Neurelis, INC. | $631.65 | 2020-2024 | Valtoco |
| Amneal Pharmaceuticals LLC | $601.21 | 2019-2024 | Rytary |
| Supernus Pharmaceuticals, INC. | $594.97 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $570.79 | 2019-2024 | Ztlido |
| Acorda Therapeutics, INC | $527.19 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $521.96 | 2019-2022 | |
| Lilly USA, LLC | $469.88 | 2019-2024 | Emgality, Reyvow |
| Adamas Pharmaceuticals, INC. | $423.83 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.70 | 2019-2021 | |
| Horizon Therapeutics Plc | $307.72 | 2019-2022 | |
| Amgen INC. | $292.48 | 2019-2024 | Aimovig |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Athari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.